We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current INTI market cap is 10.36M. The company's latest EPS is USD -0.0176 and P/E is -3.41.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.75M | -1.06M | -325k | -658k | -3.41M |
| Net Income | -2.93M | -1.26M | -499k | 11.92M | -3.03M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 900k | 132k | 59k | 11.98M | 8.95M |
| Total Liabilities | 3.43M | 3.49M | 3.68M | 3.68M | 3.67M |
| Total Equity | -2.53M | -7.32M | -3.62M | 8.3M | 5.28M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -2.71M | -825k | -220k | 11.74M | -2.7M |
| Investing | N/A | N/A | N/A | N/A | N/A |
| Financing | 2.4M | 96k | 176k | 180k | -411k |
| Market Cap | 10.36M |
| Price to Earnings Ratio | -3.41 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.17 |
| Price to Book Ratio | 1.96 |
| Dividend Yield | - |
| Shares Outstanding | 172.32M |
| Average Volume (1 week) | 8.73k |
| Average Volume (1 Month) | 52.96k |
| 52 Week Change | -49.92% |
| 52 Week High | 0.1376 |
| 52 Week Low | 0.03355 |
| Spread (Intraday) | 0.03 (37.3%) |
| Company Name | Inhibitor Therapeutics Inc (QB) |
| Address |
108 w. 13th street suite 100 wilmington, delaware 19801 |
| Website | https://www.inhibitortx.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
